title: Evaluating treatment of hepatitis C for hemolytic anemia management.
authors.affiliation: Department of Mathematics, University of Florida, Gainesville, FL, USA. swati@math.ufl.edu
authors.forename: Swati
authors.initials: S
authors.lastname: DebRoy
authors.forename: Christopher
authors.initials: C
authors.lastname: Kribs-Zaleta
authors.forename: Anuj
authors.initials: A
authors.lastname: Mubayi
authors.forename: Gloriell M
authors.initials: GM
authors.lastname: Cardona-Meléndez
authors.forename: Liana
authors.initials: L
authors.lastname: Medina-Rios
authors.forename: MinJun
authors.initials: M
authors.lastname: Kang
authors.forename: Edgar
authors.initials: E
authors.lastname: Diaz
mesh_terms: D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000517:prevention & control*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D003198:Computer Simulation; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects*; D008954:Models, Biological; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D012254:Ribavirin; D007372:Interferons